Glaxo scores with Olympic anti-doping ads

GSKSmallLogo

Throwing its weight--and $31 million--behind the London Olympics qualified GlaxoSmithKline ($GSK) as a good corporate citizen. But as it turns out, the company is getting its money's worth in publicity. Thanks to a savvy marketing move--setting up an anti-doping lab--Glaxo has made so many headlines and newscasts that it would be easier to count which major media haven't run a feature.

Now, Glaxo's Olympic advertising is turning heads. TV ads, posters and billboards have gone up all over the U.K., focusing, again, on the anti-doping lab. And these are no seen-it-all-before Olympic-ring celebrations. Glaxo's TV commercials do take the usual approach of featuring home-country athletes, but forego hackneyed crowd shots and swelling, sentimental music.

 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Take the commercial featuring British track star Marlon Devonish. It begins in a crowded, screaming stadium, but then swoops through Devonish's body with its swarming red blood cells, firing synapses, expanding lungs, and fast-beating heart--interspersed with rapid-fire images of fast-moving forces of nature. A tornado, for instance. When the visual stream shows hair standing on end, ours did, too.

It all ends with an anti-doping tagline: The Crowd Is My Only Drug. The implication: Devonish's body is gearing up for action quite well on its own adrenaline rush, thank you.



Related Articles:
As blockbuster drugs fade, so does TV advertising
Glaxo sales slump in Europe, U.S. on price cuts, generics
FDA cites promos from Astellas, Novartis and GSK

Suggested Articles

The FDA has handed down its decision against Sanofi and Lexicon's Zynquista.

Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.

The new Alcon shares will be listed on the Swiss Exchange and the New York Stock Exchange on April 9 under the ticker “ALC.”